A multidisciplinary group of tuberculosis experts from the TBnet and RESIST-TB networks have reached a consensus on key issues related to the molecular prediction of Mycobacterium tuberculosis antibiotic sensitivity or resistance and its clinical implications. The consensus document provides guidance for the design of therapeutic regimens and the optimization of treatments, and is intended to help clinicians manage tuberculosis patients. The paper, published in The Lancet Infectious Diseases and led by Dr José Domínguez from the Germans Trias i Pujol Research Institute (IGTP), is an update of a similar statement made in 2016. The publication presents a review of the current tools to rapidly identify resistance to drugs used in the treatment of tuberculosis. Read more here.
top of page
Recent Posts
See AllA recent study on the incidence of MDR-TB in children and teens revealed that the prevalence has resurged. there was a 10 year drop from...
The Stop TB Partnership announced a major price reduction on bedaquiline. The cost per treatment course was slashed by over 50%,...
The shutdown and dismantling of USAID has had large ramifications for TB services. As one of the largest funding sources for TB, the...
bottom of page
Commentaires